Non-healing Wound, Venous Insufficiency of Leg, Venous Leg Ulcer, Venous Stasis, Venous Stasis Ulcer, Venous Ulcer, Wound, Wound Heal
Conditions
Keywords
Tissue Repair, Glucoprime, TR Therapeutics, Debridement, VLU
Brief summary
The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.
Detailed description
This is an outpatient, randomized, parallel- group, double-blind, multicenter, 16-week study with 2 treatment arms: TR987 0.1% gel + Standard of Care and Standard of Care alone in participants who have a non-healing Venous Leg Ulcer (VLU). The primary objective is to assess the proportion of participants with Complete Closure of the target ulcer at or before the Week-16 end of treatment (EOT) visit. Secondary endpoints include: * Proportion of participants with Complete Closure of the target ulcer at or before the Week 16 visit AND for whom the ulcer remains closed at the 3-Month Follow-Up visit after such closure (a composite endpoint). * Change from baseline in participant's perception of pain level at 12 weeks. * Percent change from baseline in the target ulcer area at 12 and 16 weeks. In the event of Complete Closure before these time points, the target ulcer area will be deemed to be zero at those time points for purposes of calculation of this endpoint. * Proportion of participants with Complete Closure of the target ulcer at or before the Week 12 treatment visit. * Proportion of participants with any significant reduction in pain at or before 12 weeks. There are also some supplementary and safety endpoints.
Interventions
6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
OTHERStandard of care
Standard of Care (wound cleansing/dressings and compression bandaging)
Sponsors
TR Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Particpants will be randomized to either TR987 1% gel + Standard of Care and Standard of Care alone. Sponsor, particpant, and Investigator/Outcomes Assessor will be masked throughout the treatment period.
Intervention model description
This is an outpatient, randomized, parallel- group, double-blind, multicenter, 16-week study with 2 treatment arms: TR987 0.1% gel + Standard of Care and Standard of Care alone in participants who have a non-healing Venous Leg Ulcer (VLU).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults 18 years and older * Venous insufficiency has been clinically diagnosed clinically and medically confirmed. * Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control. * The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization. * Target ulcer age must be ≥ 4 weeks at Screening. * Participants must have adequate arterial flow as confirmed by ABI/TBI, TB, SPP, TCPo2, or Duplex Doppler. * Body mass index (BMI) ≤ 50 kg/m2. * HbA1C ≤12%.
Exclusion criteria
* Target ulcer has been treated with prohibited medications or therapies. * History of radiation at the target ulcer site. * Target ulcer decreases in area by 30% or more during screening period. * History of osteomyelitis at the target ulcer within 6 months of screening. * History of cancer in the preceding 5 years (except as noted in the protocol). * Participants considered nutritionally deficient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants with Complete Closure of the target ulcer at or before the Week-16 end of treatment (EOT) visit. | 16 weeks | Patient count |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants with Complete Closure of the target ulcer at or before the Week 16 visit AND for whom the ulcer remains closed at the 3-Month Follow-Up visit after such closure (a composite endpoint). | 16 weeks | Patient count |
| Change from baseline in participant's perception of pain level at 12 weeks. | 12 weeks | Pain to be measured on a 10 point numeric rating scale |
| Percent change from baseline in the target ulcer area at 12 and 16 weeks. In the event of Complete Closure before these time points, the target ulcer area will be deemed to be zero at those time points for purposes of calculation of this endpoint. | 12 and 16 weeks | Measure the are of the wound in cm2 at baseline and at 12 and 16 weeks and calculate the percentage change |
| Proportion of participants with Complete Closure of the target ulcer at or before the Week 12 treatment visit. | 12 weeks | Count the number of patients with complete closure and divide by the total number of patients |
| Proportion of participants with any significant reduction in pain at or before 12 weeks. | 12 weeks | Count the number of patients with any significant reduction in pain and divide by the total number of patients |
Countries
Australia, United States
Contacts
Primary ContactAnhthu Nguyen Vice President, Global Clinical Operations
Outcome results
None listed